Hyperaldosteronism Among Black and White Subjects With Resistant Hypertension-Reference-Cited by-同舟云学术

Hyperaldosteronism Among Black and White Subjects With Resistant Hypertension

Published:2002-12 Issue:6 Volume:40 Page:892-896
ISSN:0194-911X
Container-title:Hypertension
language:en
Short-container-title:Hypertension

Author:

Calhoun David A.¹,Nishizaka Mari K.¹,Zaman Mohammad A.¹,Thakkar Roopal B.¹,Weissmann Paula¹

Affiliation:

1. From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (M.K.N., M.A.Z.), and the Veterans Affairs Medical Center (D.A.C.), Birmingham, Ala; St. Joseph Mercy Hospital (R.B.T.), Ypsilanti, Mich; and the Hypertension Department, Favaloro Foundation (P.W.), Buenos Aires, Argentina.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Internal Medicine

Reference26 articles.

1. HIGH INCIDENCE OF PRIMARY ALDOSTERONISM IN 199 PATIENTS REFERRED WITH HYPERTENSION

2. Screening for primary aldosteronism without discontinuing hypertensive medications: Plasma aldosterone-renin ratio

3. EVIDENCE THAT PRIMARY ALDOSTERONISM MAY NOT BE UNCOMMON: 12% INCIDENCE AMONG ANTIHYPERTENSIVE DRUG TRIAL VOLUNTEERS

Cited by 626 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epidemiological point of view;Genetics and Epigenetics of Genitourinary Diseases;2025

2. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension;European Heart Journal;2024-08-30

3. Utility of Adrenal Vein Sampling With and Without Ultra‐Low Dose ACTH Infusion in the Diagnostic Evaluation of Primary Aldosteronism;Endocrinology, Diabetes & Metabolism;2024-08-29

4. High serum levels of reactive nitrogen species and low total antioxidant capacity in patients with resistant hypertension compared to those in age- gender matched healthy controls, controlled hypertension and follow up with propranolol treatment in the extended APPROPRIATE trial;BMC Research Notes;2024-08-13

5. First‐in‐human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor;Clinical and Translational Science;2024-08